HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Focal segmental glomerulosclerosis — Clinical Guidelines

Overview

Focal segmental glomerulosclerosis (FSGS) is a glomerular disease characterized by proteinuria and frequent progression to end-stage renal disease, often recurring after kidney transplantation 1 2 5 10 11.

Diagnosis

Clinical Presentation: Nephrotic syndrome with heavy proteinuria 1 3 6.

Biopsy: Essential for diagnosis, identifying characteristic segmental glomerular lesions 1 10 19.

Electron Microscopy: Useful in early detection and identifying podocyte foot process effacement 19.

Immunosuppressive Evaluation: Consideration of potential secondary causes through serologic testing 6 14.

Management

First-Line Treatments:

- Angiotensin-Converting Enzyme (ACE) Inhibitors/Angiotensin Receptor Blockers (ARBs): To reduce proteinuria 3 6 14. - Calcineurin Inhibitors: Mycophenolate mofetil with oral dexamethasone pulses or cyclosporine in steroid-resistant cases 12 (Evidence: Moderate).

Adjunctive Therapies:

- Sparsentan: Dual endothelin-angiotensin receptor antagonist shown to reduce proteinuria in phase 3 trials 3 (Evidence: Strong). - Dapagliflozin: Emerging evidence suggests potential benefits in FSGS patients in chronic kidney disease trials 7 (Evidence: Moderate). - Bleselumab: Anti-CD40 monoclonal antibody in early phase 2 trials for preventing recurrence post-transplant 2 (Evidence: Weak). - Extracorporeal Plasma Therapy (EPT): Including plasmapheresis and immunoadsorption, with variable efficacy in systematic reviews 4 (Evidence: Moderate).

Special Populations

Pediatrics: Significant practice variation in management; plasmapheresis and immunosuppressive therapies are commonly used 1 9.

Post-Transplant: High risk of recurrence (~25%) with poor allograft outcomes; prophylactic strategies are under investigation 2 5 10.

Comorbidities: FSGS in patients with polyautoimmunity (e.g., Sjögren's syndrome) may reflect severe immune dysregulation 8.

Key Recommendations

Use ACE inhibitors/ARBs for proteinuria reduction in FSGS patients (Evidence: Strong) 3 6 14.

Consider sparsentan as an adjunctive therapy for managing proteinuria in FSGS (Evidence: Strong) 3.

Evaluate and manage secondary causes through comprehensive serologic testing in patients with suspected secondary FSGS (Evidence: Moderate) 6 14.

Monitor pediatric patients closely due to significant variability in management practices and outcomes 1 9 (Evidence: Expert opinion).

Prophylactic strategies for preventing FSGS recurrence post-transplant are needed but currently under investigation 2 5 10 (Evidence: Weak).

References

1 Verghese PS, Rheault M, Matossian D, Kilduff S, Switalski M, Riordan M et al.. Transcontinental Practice Patterns in Pediatric Recurrent Focal Segmental Glomerulosclerosis: Barriers to Consensus and Adequately Powered Studies. Pediatric transplantation 2026. link 2 Shoji J, Goggins WC, Wellen JR, Cunningham PN, Johnston O, Chang SS et al.. Efficacy and Safety of Bleselumab in Preventing the Recurrence of Primary Focal Segmental Glomerulosclerosis in Kidney Transplant Recipients: A Phase 2a, Randomized, Multicenter Study. Transplantation 2024. link 3 Rheault MN, Alpers CE, Barratt J, Bieler S, Canetta P, Chae DW et al.. Sparsentan versus Irbesartan in Focal Segmental Glomerulosclerosis. The New England journal of medicine 2023. link 4 Miao J, Krisanapan P, Tangpanithandee S, Thongprayoon C, Mao MA, Cheungpasitporn W. Efficacy of extracorporeal plasma therapy for adult native kidney patients with Primary FSGS: a Systematic review. Renal failure 2023. link 5 Bai J, Zhang T, Wang Y, Cao J, Duan Z, Ji L et al.. Incidence and risk factors for recurrent focal segmental glomerulosclerosis after kidney transplantation: a meta-analysis. Renal failure 2023. link 6 Hodson EM, Sinha A, Cooper TE. Interventions for focal segmental glomerulosclerosis in adults. The Cochrane database of systematic reviews 2022. link 7 Wheeler DC, Jongs N, Stefansson BV, Chertow GM, Greene T, Hou FF et al.. Safety and efficacy of dapagliflozin in patients with focal segmental glomerulosclerosis: a prespecified analysis of the dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2022. link 8 Lucassen EA, Vlasveld T, Hommes N. FSGS tip lesion in polyautoimmunity including Sjögren's syndrome. The Netherlands journal of medicine 2020. link 9 Bouts A, Veltkamp F, Tönshoff B, Vivarelli M. European Society of Pediatric Nephrology survey on current practice regarding recurrent focal segmental glomerulosclerosis after pediatric kidney transplantation. Pediatric transplantation 2019. link 10 Han MH, Kim YJ. Practical Application of Columbia Classification for Focal Segmental Glomerulosclerosis. BioMed research international 2016. link 11 Cravedi P, Kopp JB, Remuzzi G. Recent progress in the pathophysiology and treatment of FSGS recurrence. American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons 2013. link 12 Deegens JK, Wetzels JF. Immunosuppressive treatment of focal segmental glomerulosclerosis: lessons from a randomized controlled trial. Kidney international 2011. link 13 Ceri M, Kurultak I, Unverdi S, Altay M, Duranay M. An unusual cause of focal segmental glomerulosclerosis: psoriasis vulgaris. Renal failure 2010. link 14 Meyrier A. An update on the treatment options for focal segmental glomerulosclerosis. Expert opinion on pharmacotherapy 2009. link 15 Singh D, West K, Kamal K, Gupta R, Belitsky P, Kiberd B et al.. Early recurrence of primary focal segmental glomerulosclerosis in an older cadaveric renal allograft recipient resistant to plasmapheresis. Urology 2006. link 16 Mochizuki H, Joh K, Matsuyama N, Imadachi A, Usui N, Eto Y. Focal segmental glomerulosclerosis in a patient with Prader-Willi syndrome. Clinical nephrology 2000. link 17 Pedagogos E, Flanagan G, Francis DM, Becker GJ, Danks DM, Walker RG. A case of craniomandibular dermatodysostosis associated with focal glomerulosclerosis. Pediatric nephrology (Berlin, Germany) 1995. link 18 Panner BJ, Berkowitz P. Glomerular capsular herniation in focal glomerular sclerosis. American journal of kidney diseases : the official journal of the National Kidney Foundation 1992. link80958-9) 19 Salwa-Zurawska W, Bortkiewicz E, Turczuk-Bierła I, Maciejewski J. Focal segmental glomerulosclerosis in children. Patologia polska 1992. link 20 Datta AR, Sakhuja V, Minz M, Joshi K, Chugh KS. Recurrent focal segmental glomerulosclerosis after renal transplantation. The International journal of artificial organs 1991. link 21 Lines DR, Coleman M, Gallus A. Focal glomerulosclerosis treated with heparin. Archives of disease in childhood 1989. link 22 Trainin EB, Gomez-Leon G. HLA identity in siblings with focal glomerulosclerosis. The International journal of pediatric nephrology 1983. link 23 Hardwicke J, White RH, Williams A. Molecular size of IgG in patients with focal glomerulosclerosis. Clinical nephrology 1976. link

Focal segmental glomerulosclerosis